Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: Updated review
- 1 February 2019
- journal article
- review article
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 18 (1), 10-15
- https://doi.org/10.1111/jocd.12828
Abstract
Botulinum Toxin Type A is a potent neurotoxin that is produced by a gram-positive bacteria clostridium botulinum. Its utilization in the treatment of various medical condition has expanded over the years in both medical and esthetic uses. It is being preferred by most physicians due to its efficacy and lack of side effects. It can be used as monotherapy or combined therapy. The aim of this review study was to show the role and mechanism of action of Botulinum toxin type A in the treatment and prevention of hypertrophic scars and keloids. The clear mechanisms underlying hypertrophic scars and keloids are still not clearly understood; however, the mechanism of action of Botulinum toxin type A has been shown to include action on wound tension, action on collagen, and action on fibroblasts. Different randomized controlled trials, double-blind, and placebo-controlled studies have been conducted to investigate its use in treatment and prevention of hypertrophic scars and keloids, and it still is one of the active areas of research in Dermatology and related fields. Method: In March 2018, we performed a literature search in PubMed for clinical studies, clinical trials, case reports, controlled trials, randomized controlled trials, and systemic reviews. The search terms we used were "BOTULINUM TOXIN" AND "HYPERTROPHIC SCARS" OR "KELOIDS" (from 1980). The search resulted in 1000 articles, out of these 35 articles met our inclusion exclusion criteria. Our inclusion criteria included relevant original articles relevant, critical systemic reviews, and crucial referenced articles, exclusion criteria included duplicates and articles not published in English language. We have reviewed these papers to show the role and mechanism of action of Botulinum toxin type A in the treatment and prevention of hypertrophic scars and keloids.Keywords
Funding Information
- National Natural Science Foundation of China (81573072)
- Government of Jiangsu Province (QNNRC 2016583, 2017)
- Nanjing Medical University
This publication has 31 references indexed in Scilit:
- Keloid scars and treatment with Botulinum Toxin Type A: The Belfast experienceJournal of Plastic, Reconstructive & Aesthetic Surgery, 2013
- Botulinum Toxin to Minimize Facial ScarringFacial Plastic Surgery, 2012
- Effects of Botulinum Toxin Type A on Collagen Deposition in Hypertrophic ScarsMolecules, 2012
- Treatment of a Painful Keloid with Botulinum Toxin Type AAmerican Journal of Physical Medicine & Rehabilitation, 2010
- Intralesional Botulinum Toxin Type A Injection as a New Treatment Measure for KeloidsPlastic and Reconstructive Surgery, 2009
- Treatment of Hypertrophic Scars With Intralesional Botulinum Toxin Type A Injections: A Preliminary ReportAesthetic Plastic Surgery, 2009
- Botulinum toxin type A affects cell cycle distribution of fibroblasts derived from hypertrophic scarJournal of Plastic, Reconstructive & Aesthetic Surgery, 2008
- Hypertrophic Scar Formation Following Burns and Trauma: New Approaches to TreatmentPLoS Medicine, 2007
- Botulinum Toxin to Improve Facial Wound Healing: A Prospective, Blinded, Placebo-Controlled StudyMayo Clinic Proceedings, 2006
- Botulinum Toxin Injection into Extraocular Muscles as an Alternative to Strabismus SurgeryOphthalmology, 1980